Table of Contents Table of Contents
Previous Page  288 / 398 Next Page
Information
Show Menu
Previous Page 288 / 398 Next Page
Page Background

283

vival benefit when compared to ‘watch and wait’ (WW) [

R

= 0.50,

P

= 0.18, 95% CI = 0.19–1.36,

I

2

= 48%]. There was strong evi-

dence favouring END at an earlier disease stage with the weighted

odds of regional recurrence 9 times lower than the WW group

[OR = 0.09,

P

< 0.0001, 95% CI = 0.05–0.16,

I

2

= 0%].

Conclusions:

END is the gold standard treatment for small tongue

SCC without clinically detectable nodes. Although there appeared

to be no superior survival benefit subjecting patients to END, sub-

sequent management can be guided by the histological finding

from the neck specimen.

Observation remains a conservative alternative to early neck

intervention provided a stringent follow up scheme is strictly

adhered to. Immediate surgical intervention when lymph node

remains small is the key to high salvage rate and overall survival

outcome.

http://dx.doi.org/10.1016/j.ijom.2017.02.951

Nasogastric feeding tube placement in head and neck

oncology patients

R.J. Clark

∗

, T.D. Dickens

The University of Bristol, Bristol, United Kingdom

Background:

Nasogastric (NG) feeding is important for a suc-

cessful recovery in many postoperative head and neck cancer

patients. There have been 21 deaths in England since 2005 as

a result of misplaced feeding tubes. Misplaced NG feeding tubes

are a ‘never event’ in the Leeds Teaching Hospital Trust.

Method:

Retrospective analysis of the notes of 80 head and neck

oncology patients who underwent surgery between 2014 and 2015

and required NG feeding tube (NGFT) postoperative placement.

Completed over four three-monthly cycles.

Results:

For the first six months, 50% of patients had no record

of NGFT postoperative placement and in 70% of cases the length

of insertion was not recorded. After the introduction of a new

oncology clerking proforma and further staff training, placement

was correctly recorded in 100% of patients.

Conclusion:

Repeat audit cycles and analysis of the data localised

the failures in documentation completion to placement of the

NGFT in theatres. With a new oncology clerking proforma and

further training to the entire oral and maxillofacial surgery team, I

successfully improved the completion rate of the NGFT placement

documentation.

http://dx.doi.org/10.1016/j.ijom.2017.02.952

The immunological impact of chemotherapy on the tumour

microenvironment of oral squamous cell carcinoma

S. Domae

∗

, H. Takakura, Y. Kunisada, T. Ono, A. Sasaki,

I. Asahina

Nagasaki University Graduate School of Biomedical Sciences,

Japan

Background:

The immune system plays an important role in

the development and progression of cancers, including oral squa-

mous cell carcinoma (OSCC). However, little is known about the

immune response in the tumour microenvironment after neoadju-

vant chemotherapy.

Objective:

To investigate the immunological impact of

chemotherapy in the tumour microenvironment of OSCC.

Methods:

We retrospectively analysed a degree of immune cell

infiltration and relevance of the programmed death ligand-1 (PD-

L1) expression in surgically resected eighteen OSCC specimens

from patients with or without pretreatment of certain chemother-

apy.

Results:

No distinct difference was observed on the degree of

immune-cell infiltration between two groups. A decreased num-

ber of programmed death-1 (PD-1) positive cells were found in

the specimens of cancer nest of the neoadjuvant chemotherapy

group. In the without neoadjuvant chemotherapy group, 80%spec-

imens showed intermediate to strong expression of PD-L1 protein.

Whereas most of the specimens of the neoadjuvant chemotherapy

group (75%) showed weak expression.

Conclusion:

Neoadjuvant chemotherapy in OSCC is useful to

induce the number of tumour-infiltrating lymphocytes in the

tumour microenvironment. And it was revealed that the expression

of PD-L1 changed by the chemotherapeutic agents.

http://dx.doi.org/10.1016/j.ijom.2017.02.953

The rate of phrenic nerve injury following neck dissection for

head and neck cancer and its impact on length of hospital

stay

O. Dugena

∗

, S. Islam, J. Hayter

Department of Maxillofacial/Head and Neck Surgery University

Hospitals Leicester, Leicester, United Kingdom

Background:

The published rate of phrenic nerve injury follow-

ing head and neck cancer surgery is highly variable and there is

a paucity of data regarding its impact on postoperative recovery.

Our aim was to investigate the prevalence of phrenic nerve dam-

age following neck dissection for oral cavity malignancy and to

explore its association with postoperative length of hospital stay.

Method:

We reviewed the clinical records of 100 consecutive

patients who underwent a neck dissection for oral cancer. We

assessed both the pre and postoperative chest radiographs for

evidence of phrenic nerve injury. Data pertaining to stage of dis-

ease, type of neck dissection, pre-existing respiratory disorders,

patients’ performance status and postoperative length of hospital

stay were collected from the medical treatment records.

Findings:

93 patients met our inclusion criteria. 9% had a radio-

logical evidence of postoperative unilateral phrenic nerve injury.

Only 1 patient underwent a radical neck dissection and in most

patients (

n

= 7) the nerve injury was noted incidentally on chest

radiographs after a selective neck dissection. The median length of

stay was compared and patients with phrenic nerve injury stayed

for median of 16 days versus a median of 15 days for the overall

cohort (Mann–Whitney

U

,

P

= 0.86).

Conclusion:

Unilateral phrenic nerve injury is a common inciden-

tal finding following neck dissection. Most of these are usually

transient or found to have no clinical significance. Our study

demonstrates a rate of unilateral phrenic nerve injury to be 9%

with no statistically significant association with increased length

of hospital stay.

http://dx.doi.org/10.1016/j.ijom.2017.02.954